SCHEMBL6570928

SCHEMBL6570928

[c]1cccc(CCCc2ccccc2)c1CCCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.42
SIGMAR1 Q99720 5/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 2/20 0.38
BID P55957 1/20 0.38
BCL2L1 Q07817 1/20 0.38
MCL1 Q07820 1/20 0.38
BAK1 Q16611 1/20 0.38
IDO1 P14902 1/20 0.37
HDAC3 O15379 1/20 0.37
MAPK1 P28482 1/20 0.37
ADRA1A P35348 1/20 0.37
HDAC4 P56524 1/20 0.37
SLC6A3 Q01959 1/20 0.37
HDAC1 Q13547 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332631 0.92 KCNH2 (0.40) HTR2ASIGMAR1ADRA1ASLC6A3
SCHEMBL140371 0.88 ADRA1A (0.40) HTR2AHDAC3MAPK1ADRA1AHDAC4
SCHEMBL6468704 0.87 KCNH2 (0.45) HTR2ASIGMAR1BIDBCL2L1MCL1
SCHEMBL10894648 0.87 KCNH2 (0.49) HTR2ASIGMAR1SLC6A3
SCHEMBL7426036 0.87 CYP2A6 (0.46)
SCHEMBL8095256 0.87 CYP2A6 (0.46)
SCHEMBL7431316 0.85 ABCB1 (0.44) SMN1; SMN2
SCHEMBL8083439 0.85 ABCB1 (0.44) SMN1; SMN2
SCHEMBL10422126 0.85 HTR1A (0.43) HTR2AMAOAMAOBIDO1SMN1; SMN2
SCHEMBL8091440 0.82 ABCB1 (0.52) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1404325-A2 METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY GUILFORD PHARMACEUTICALS INC. (US) 2004-04-07 EP disclosed
WO-2002096420-A2 METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY GUILFORD PHARMACEUTICALS INC. (US) 2002-12-05 WO disclosed
EP-1127049-A1 BRIDGED HETEROCYCLIC DERIVATIVES GPI NIL Holdings, Inc. (US) 2001-08-29 EP disclosed
EP-1085854-A1 N-LINKED SULFONAMIDE OF HETEROCYCLIC THIOESTER HAIR GROWTH COMPOUNDS AND USES GPI NIL Holdings, Inc. (US) 2001-03-28 EP disclosed
US-6121273-A ISOMERASE INHIBITORS EFFECTIVE AGAINST NEUROLOGICAL DISORDERS, I.E. PARKINSON'S DISEASE, ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS; SIDE EFFECT REDUCTION GPI NIL HOLDINGS, INC (US) 2000-09-19 US disclosed
EP-1011650-A1 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS Amgen Inc., (US) 2000-06-28 EP disclosed
EP-0859614-A4 ROTAMASE ENZYME ACTIVITY INHIBITORS GUILFORD PHARM INC (US) 2000-04-26 EP disclosed
WO-2000016603-A2 BRIDGED HETEROCYCLIC DERIVATIVES GPI NIL HOLDINGS, INC. (US) 2000-03-30 WO disclosed
US-6004993-A TREATMENT OF ALOPECIA IN ANIMALS GPI NIL HOLDINGS, INC. (US) 1999-12-21 US disclosed
WO-1999062489-A1 N-LINKED SULFONAMIDE OF HETEROCYCLIC THIOESTER HAIR GROWTH COMPOUNDS AND USES GPI NIL HOLDINGS, INC. (US) 1999-12-09 WO disclosed
WO-1999014998-A2 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS AMGEN INC. (US) 1999-04-01 WO disclosed
EP-0859614-A1 ROTAMASE ENZYME ACTIVITY INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-08-26 EP disclosed
WO-1997016190-A1 ROTAMASE ENZYME ACTIVITY INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-05-09 WO disclosed